The Sensitive Genes for Cervical Cancer: Two-Sample Mendelian Randomization with Experimental Validation DOI Creative Commons
Rong Zhang, Shengjun Chai, Qihang Chen

и другие.

International Journal of Women s Health, Год журнала: 2025, Номер Volume 17, С. 1511 - 1532

Опубликована: Май 1, 2025

Cervical cancer, the fourth leading cause of female cancer mortality globally, faces treatment limitations due to drug resistance and few therapeutic options. This study seeks identify novel targets address this urgent clinical need. Our team identified differentially expressed genes (DEGs) in cervical using gene expression omnibus (GEO) datasets. Subsequently, Mendelian randomization (MR) analysis causal gene-cancer relationships, followed by enrichment The Cancer Genome Atlas (TCGA) validation. Finally, we further validated functions selected target cells analyzed their Gene Set Enrichment Analysis (GSEA) results, sensitivity, prognostic value. We 2,801 upregulated 1,646 downregulated DEGs. MR 21 key cancer-associated (14 upregulated, 7 downregulated), with TCGA validation confirming significant differential patterns. Among them, studies have examined these core genes, particularly MERTK SERPINF1, cancer. Experiments showed that SERPINF1 play a role These help grow, spread, invade surrounding tissue. Mechanistically, regulates immune infiltration, whereas modulates chromosomal activity. Clinically, enhances overall survival (OS), disease-specific (DSS), progression-free interval (PFI) individuals Moreover, discovered several commonly used drugs for treatment, like paclitaxel, high efficacy against SERPINF1. uncovers as critical regulators progression survival, offering mechanistic insights into roles tumor behavior microenvironment. findings provide foundation precision therapies, restoration inhibition promising strategies. Clinical translation could current limitations.

Язык: Английский

The Sensitive Genes for Cervical Cancer: Two-Sample Mendelian Randomization with Experimental Validation DOI Creative Commons
Rong Zhang, Shengjun Chai, Qihang Chen

и другие.

International Journal of Women s Health, Год журнала: 2025, Номер Volume 17, С. 1511 - 1532

Опубликована: Май 1, 2025

Cervical cancer, the fourth leading cause of female cancer mortality globally, faces treatment limitations due to drug resistance and few therapeutic options. This study seeks identify novel targets address this urgent clinical need. Our team identified differentially expressed genes (DEGs) in cervical using gene expression omnibus (GEO) datasets. Subsequently, Mendelian randomization (MR) analysis causal gene-cancer relationships, followed by enrichment The Cancer Genome Atlas (TCGA) validation. Finally, we further validated functions selected target cells analyzed their Gene Set Enrichment Analysis (GSEA) results, sensitivity, prognostic value. We 2,801 upregulated 1,646 downregulated DEGs. MR 21 key cancer-associated (14 upregulated, 7 downregulated), with TCGA validation confirming significant differential patterns. Among them, studies have examined these core genes, particularly MERTK SERPINF1, cancer. Experiments showed that SERPINF1 play a role These help grow, spread, invade surrounding tissue. Mechanistically, regulates immune infiltration, whereas modulates chromosomal activity. Clinically, enhances overall survival (OS), disease-specific (DSS), progression-free interval (PFI) individuals Moreover, discovered several commonly used drugs for treatment, like paclitaxel, high efficacy against SERPINF1. uncovers as critical regulators progression survival, offering mechanistic insights into roles tumor behavior microenvironment. findings provide foundation precision therapies, restoration inhibition promising strategies. Clinical translation could current limitations.

Язык: Английский

Процитировано

0